Santa Clara, CA, July 18, 2011 Cell Biosciences, Inc. today announced that it has changed its name to ProteinSimple to clearly reflect the Company's core mission in protein research.

The Company's goal is simply to help researchers gain a better understanding of proteins and their role in disease. ProteinSimple's strategy is to power protein research by making it simpler and more quantitative, ultimately revealing new insights into the true nature of proteins.

Over the past 3 years, ProteinSimple has built a unique portfolio of protein analysis tools including systems for traditional protein imaging, systems to probe the structure and purity of protein based therapeutics and systems that provide fresh insight into protein signaling. Later this year, the Company will launch a revolutionary product that is expected to completely reinvent and automate the Western Blot the most widely used technique in protein analysis.

The company expects to generate over $40 million in revenue in 2011, and has grown significantly from $1 million in 2008. ProteinSimple has over 170 employees and more than 10,000 systems installed around the world. In the last 18 months, the Company has made 4 acquisitions in the protein analysis space and raised over $60 million in venture capital.

“We are all very excited about our new ProteinSimple identity,” commented Tim Harkness, President and CEO of ProteinSimple. “After a period of tremendous growth and change, we felt it was important to speak clearly to our customers about our vision and goals. ProteinSimple captures our entire value proposition and culture in a single word. The employees of ProteinSimple are fully committed to helping researchers gain a deeper understanding of proteins and to building a unique protein analysis pure-play.”

About ProteinSimple

ProteinSimple's goal is simply to help researchers gain a better understanding of proteins and their role in disease. The Company's strategy is to power protein research by making it simpler and more quantitative, ultimately revealing new insights into the true nature of proteins. ProteinSimple has built a unique portfolio of protein analysis tools including systems for traditional protein imaging, systems to probe the structure and purity of protein based therapeutics and systems that provide fresh insight into protein signaling. ProteinSimple has over 170 employees, more than 10,000 systems installed around the world and is headquartered in Santa Clara, California. For more information, visit www.proteinsimple.com.

Santa Clara, CA, September 8, 2009 Cell Biosciences, Inc. today announced that it has completed its acquisition of Alpha Innotech Corp. (OTC BB: APNO.OB). The stockholders of Alpha Innotech have approved the transaction, and all regulatory and other conditions have been satisfied. Pursuant to the merger agreement announced on September 8, 2009, former Alpha Innotech stockholders will receive $1.50 per share, or approximately $17.9 million in cash.


(Cell Biosciences hasChanged Name to ProteinSimple.)

细胞异质性是肿瘤研究，干细胞研究，免疫学研究的极其重要的研究方向。单细胞研究是

分析细胞异质性的主要手段。单细胞组学研究也是jing准医学首要的研究领域。

美国ProteinSimple公司首推基于芯片Western Blot技术，进行单个细胞蛋白质表达水平定

量分析系统: Milo.

Milo具有极其强大的功能：

1. 单张芯片进行1000个单细胞western blot

2. 每个单细胞可进行数十个靶蛋白检测

3. 仅需使用Western blot验证抗体，具有抗体通用性

4. 基于western blot技术，蛋白进行分离后检测，提高免疫学检测特异性

5. 全程检测只需4小时

2020年9月10-12日，由浙江省药学会生物制药专业委员会、浙江省海高会生物医药分会和生物制药稳定性论坛公众号共同主办的“2020生物制药稳定性论坛---助力生物药研发：解决生物制药研发和产业化过程中极具挑战的稳定性问题”在杭州召开。

来自国内外企业界、高校、监管部门等生物制药稳定性领域的知名专家、学者到会，进行了精彩的主题报告。

MFI作为ProteinSimple用于药物制剂优化开发中检测不溶性颗粒以及颗粒物形态分析的技术，备受客户推崇。

ProteinSimple作为ling先的生命科学仪器制造商和技术提供商，参加了本次盛会。

ProteinSimple大中华区应用技术经理杜颖颖博士在会上做了精彩报告：“生物药稳定性表征整体解决方案”。

PPT分享如下：